The PRC (polycomb repressive complex) 2 contains three core proteins EZH2, SUZ12 and EED, in which the SET domain of EZH2 mediates the histone methyltransferase activity. This induces tri- 
of the DNA methyltransferases DNMT1, DNMT3a and DNMT3b (22, 23) . DNMTs function to transfer a methyl group from S-adenosyl-methionine (SAM) to the 5' position of cytosine in the CpG dinucleotides in the promoters of genes, thereby maintaining a consistent pattern of epigenetic gene silencing of TSGs in cancer cells (24, 25) . DNA methylation by DNMTs also recruits HDAC activity to the promoters of silenced genes. Similar to the PRC2 complex, DNMT1 has a direct interaction with histone deacetylases HDAC1 and HDAC2 (26, 27) . Although genes methylated in cancer cells are packaged with nucleosomes containing the 3Me H3K27 mark, genes silenced in cancer by 3Me H3K27 have been shown to be independent of promoter DNA methylation, thus highlighting that 3Me H3K27 could potentially be an independent mechanism for silencing TSGs (28-30). Consistent with this, DNA methylation and transcriptional silencing of cancer genes has been shown to persist despite the depletion of EZH2, suggesting that simultaneously inhibiting DNMT1 and EZH2 would be more effective in reversing 3Me H3K27 and DNA methylation (29,31). We had previously reported that treatment with the pan-histone deacetylase (HDAC) inhibitor (HDI) panobinostat (PS, also known as LBH589, Novartis Pharmaceutical Corp) depletes the levels of EZH2, SUZ12 and EED with concomitant depletion of 3Me H3K27 in cultured and primary AML cells (19) . Within the PRC2 complex, EZH2 bound and recruited the DNMT1. PS treatment disrupted the binding between DNMT1 and EZH2, attenuated DNMT1 levels and its binding to the EZH2-targeted gene promoters, p16 and JunB (31). Additionally, treatment with PS has also been shown to deplete the leukemia associated oncoproteins accompanied by growth arrest and apoptosis of leukemia cells (32).
3-deazaneplanocin A (DZNep) is the cyclopentanyl analog of 3-deazaadenosine that inhibits the activity of S-adenosyl-L-homocysteine (AdoHcy) hydrolase, the enzyme responsible for the Nonspecific Control siRNA (#4611) was purchased from Ambion (Austin, TX). All siRNA For personal use only. on September 13, 2017. by guest www.bloodjournal.org From experiments were performed at a final concentration of 100 nM of duplex siRNA. Nucleofection of siRNAs into OCI-AML3 and HL-60 cells was performed as previously described (19).
RNA isolation and Reverse Transcription-Polymerase Chain Reaction. RNA was extracted from the cultured cells using an RNaqueous-4PCR (Applied Biosystems, Foster City, CA).
Purified RNA was quantitated and reverse-transcribed using Superscript II according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). Resulting cDNAs were used in subsequent PCR reactions for EZH2, SUZ12, EED, FBXO32, Cyclin E, p16, p21, and p27. PCR reactions for β -actin were used as an internal loading control for the PCR reactions. Amplified products were resolved on a 2% agarose gel and recorded with a UV transilluminator. Horizontal scanning densitometry was performed with ImageQuant 5.2 and band intensity was compared to β -actin.
Quantitative real time PCR analysis for EZH2, SUZ12 and EED was performed on cDNA using
TaqMan probes from Applied Biosystems (Foster City, CA). A TaqMan probe for GAPDH was used to normalize relative expression of the mRNA.
Detection and analysis of hsa-miR-101 in AML cells. For detection of hsa-miR-101 in AML
HL-60 and OCI-AML3 cells (39), miRNAs were isolated with a kit from Applied Biosystems (Foster City, CA). Total RNA was reverse transcribed with a stem loop primer included in the TaqMan hsa-miR101 microRNA assay following the manufacturer's protocol (Applied Biosystems, Foster City, CA). Expression of hsa-miR101 was detected by qPCR with a TaqMan probe specific to hsa-miR-101. Relative expression of hsa-miR101 was normalized against expression of 18S RNA.
For personal use only. on September 13, 2017. by guest www.bloodjournal.org From Cell lysis and protein quantitation. Untreated or drug-treated cells were centrifuged and the cell pellets were resuspended in 200 µL of lysis buffer as previously described (38).
SDS-PAGE and Western Blotting:
One hundred micrograms of total cell lysate was used for SDS-PAGE. Western blot analyses of DNMT1, EZH2, SUZ12, EED, BMI1, 3MeK27H3, 2MeK27H3, Acetyl K27H3, PARP, FBXO32, Cyclin E, p21, p27 and HOXA9 were performed on total cell lysates using specific antisera or monoclonal antibodies as previously described (38 However, in HL-60 cells p16 levels were undetectable ( Figure 3C ). To determine whether the DZNep mediated decline in EZH2 was mechanistically linked to upregulation of the levels of p16, 21, p27 and FBXO32, we also determined the effect of siRNA to EZH2 in OCI-AML3 cells. Figure   3D , (left panel) demonstrates that, as compared to the control siRNA, treatment with siRNA to EZH2 caused decline in mRNA of EZH2 but not of SUZ12 and EED levels. This was associated with decline in protein levels of EZH2, SUZ12 and EED ( Figure 3D , right panel). Consequently, the disruption of the PRC2 complex caused by siRNA to EZH2 increased p16, p21, p27 and FBXO32 mRNA and protein levels in OCI-AML3 cells ( Figure 3D ). Reduced EZH2 levels also caused a decline in the levels of 3Me K27H3 in OCI-AML3 cells ( Figure 3D ). Although, the precise mechanism by which DZNep promotes depletion of EZH2 is unclear, our findings demonstrate that the proteasome inhibitor BZ partially restores EZH2 levels in AML cells. DZNep treatment neither lowered the mRNA levels of EZH2 nor induced the levels of miRNA 101, which has been shown to abrogate the expression of EZH2 in prostate cancer cells (39), but diminished binding of EZH2 to its target promoters in AML cells. Further, depletion of EZH2 also led to disruption of PRC2 complex and down regulation of the levels of SUZ12 and EED in primary AML cells, as has also been previously reported for breast cancer cells (21).
Co-treatment with
These findings are consistent with our previous observation in which treatment with PS was also discovered to promote proteasomal degradation of EZH2 and disrupt PRC2, associated with depletion of the levels of SUZ12 and EED (19,31). It is also noteworthy that in AML cells DZNep treatment inhibited 3Me H3K27 but not the 3Me H3K9 or 3Me H3K79 marks, while Both mRNA and protein levels of p16, p21 and p27 were induced, although the precise mechanism(s) by which DZNep induces the levels of the three cell cycle inhibitory proteins has not been elucidated (4, 41) . Consistent with previous reports, following treatment with DZNep, the levels of the E3 ubiquitin ligase FBXO32 were also induced in AML cells (42, 43) . Levels of FBXO32 have been previously shown to be repressed by EZH2-mediated 3Me K27H3 (21).
DZNep induced FBXO32 levels were associated with decline in the levels of cyclin E, which is known to be targeted by FBXO32 (44) . Our findings demonstrating that treatment with the siRNA to EZH2 has similar effects on p16, p21, p27, cyclin E and FBXO32, indicate that DZNep mediated depletion of EZH2 is responsible for modulation of the cell cycle regulatory genes. Also, consistent with this, both present studies and previous reports have demonstrated that depletion of EZH2 inhibits cell-cycle progression through S and G2/M phases and inhibits clonogenic survival, as well as induces differentiation and apoptosis of transformed cells (18,45).
Notably, compared to either agent alone co-treatment with DZNep and the pan-HDAC inhibitor PS (LBH589) resulted in greater depletion of EZH2 and 3Me H3K27 than treatment with either 
